Table of Contents
<< Previous Issue | Jun 2020 (Vol: 2020, Issue: 6) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Novo Nordisk Acquires Cardio-Renal Focused Corvidia Therapeutics
- Section: Research & Development
-
BMS Partners with Repare on Synthetic Lethal Target Discovery for US$65 M Upfront
-
Gilead Continues Oncology Spree with US$2.2 B Arcus Deal
-
AstraZeneca Signs US$1.2 B RNA Modification Partnership with Accent Therapeutics
-
AbbVie Commits US$750 M Upfront to Oncology Collaboration with Genmab
-
GlaxoSmithKline Signs US$3 B Synthetic Lethality Alliance with IDEAYA Biosciences